Hongyao Xie

Hongyao Xie

Eli Lilly and Company - Indianapolis / United States
Others
AD Scientific Index ID: 5577909
-
person_outline Hongyao Xie's MOST POPULAR ARTICLES
1-) Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells Nature biomedical engineering 6 (11), 1284-1297, 2022
2-) Determining the mutation bias of favipiravir in influenza virus using next-generation sequencing Journal of virology 93 (2), 10.1128/jvi. 01217-18, 2019
3-) Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies Nature cancer 5 (5), 760-773, 2024
4-) Author Correction: Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cellsSJC van der Stegen, PL Lindenbergh, RM Petrovic, H Xie, MP Diop, ...Nature biomedical engineering, 202412024
5-) SYNTHETIC DUAL-COSTIMULATION FOR TCR AND TCR-LIKE TARGETED CELL THERAPIESA Dobrin, H Xie, K Perica, N Jain, M Sadelain, M HamiehHUMAN GENE THERAPY 34 (21-22), A15-A15, 202312023